Business
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1 “Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face
About this update from Knight Therapeutics, Inc.
[{"type":"image","alt":"Knight Therapeutics","displaySize":"","headline":null,"caption":"Knight Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/evslWOsosdO5XPhhsPLtpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/evslWOsosdO5XPhhsPLtpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/b93bf0a7f6cb77587518aee77ae37b63","width":300,"height":79}},"lazy":false},{"type":"text","content":"MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1","length":378,"tagName":"p"},{"type":"text","content":"“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical evidence and a novel mechanism of action. Its availability represents meaningful progress for patients who have not achieved adequate platelet responses with existing treatments, offering renewed confidence in our ability to tailor care to individual disease needs,” said Dr. Luis Meillón, Hematologist & President of SOMETH (Mexican Society of Thrombosis & Hemostasia).","length":710,"tagName":"p"},{"type":"text","content":"“The launch of TAVALISSE® in Mexico represents an important milestone in our mission to transform lives by expanding access to innovative therapies for patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics. “Chronic ITP continues to pose significant challenges for many patients, and we are proud to introduce a differentiated therapeutic treatment option for those who have not benefite...